Car-T & TME Remodeling

CAR-T and tumor microenvironment remodeling describes strategies that engineer chimeric antigen receptor T cells while modifying the tumor microenvironment that limits their activity. CAR-T therapy has shown strong activity in hematologic malignancies, but solid tumors remain difficult because the tumor microenvironment creates barriers to trafficking, infiltration, persistence, and effector function. Current research therefore treats CAR-T efficacy as a combined problem of tumor antigen recognition and microenvironment control, not as a T-cell engineering problem alone^[1][2][3].

Solid-tumor resistance involves physical, cellular, metabolic, and immune barriers. Dense extracellular matrix, abnormal vasculature, hypoxia, suppressive myeloid cells, regulatory immune cells, chemokine-receptor mismatch, tumor heterogeneity, and T-cell exhaustion restrict CAR-T cell infiltration and antitumor function. Mechanistic work supports remodeling approaches that improve trafficking, reduce immunosuppression, alter cytokine and chemokine networks, and create a tumor microenvironment that permits CAR-T activation and persistence^[1][2][3].

Disease applications focus mainly on solid tumors. In non-small cell lung cancer models, microwave ablation potentiated AXL-specific CAR-T cells by remodeling the tumor microenvironment and improving CAR-T activation, infiltration, persistence, and antitumor efficacy. Nanoengineered CAR-T biohybrids used photothermal microenvironment remodeling to destroy extracellular matrix, expand blood vessels, loosen compact tissue, stimulate chemokine secretion, and promote recruitment and infiltration of engineered CAR-T cells. These studies support combination strategies that pair CAR-T cells with local ablation, nanotechnology, stromal remodeling, or immune-modulating interventions^[4][5].

Major gaps remain in translating CAR-T and TME remodeling into durable solid-tumor therapy. The tumor microenvironment differs across tumor types and patients, so universal remodeling strategies remain difficult. Current priorities include defining predictive biomarkers, selecting rational combination therapies, improving CAR-T trafficking and persistence, reducing exhaustion, and targeting suppressive stromal and immune compartments without increasing toxicity. Future experimental planning should measure both CAR-T cell function and microenvironment remodeling endpoints, including infiltration, cytokine signaling, vascular state, extracellular matrix structure, hypoxia, and suppressive immune-cell composition^{[1][2][3][4][5]}.